ReviewOncotarget2017
Potential approaches to the treatment of Ewing's sarcoma.
Review in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 50 citations in OpenAlex.
- The Long-Term Quality of Life Study for Patients Received Chest Wall Reconstruction by Using 3D-Printed PEEK Implants.Thoracic cancer · 2026Article
- The Diagnostic Quandary of Primary Renal Ewing's Sarcoma onWorld journal of nuclear medicine · 2026Article
- Lumbar Ewing's Sarcoma Mimicking a Herniated Disc in a Young Adult: A Case Report.International medical case reports journal · 2026Article
- Bioinspired TIMP-1 Nanoparticles Mimic Extracellular Vesicle Anti-angiogenic Activity in Ewing Sarcoma.Biomaterials research · 2026Article
- In Vitro and In Vivo Efficacy of Romidepsin Alone and in Addition to Standard of Care for Treatment of Ewing Sarcoma.Cancers · 2025Article
- Ubiquitin-Specific Protease 6 mRNA Lipid Nanoparticles Ignite Antitumor Immunity and Suppress Tumorigenesis in Ewing Sarcoma.Molecular cancer therapeutics · 2025Article
- Decoding the immune landscape in Ewing sarcoma pathogenesis: The role of tumor infiltrating immune cells and immune milieu.Journal of bone oncology · 2025Review
- Primary intracranial extraosseous Ewing's sarcoma with intraspinal metastasis in children: illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- Arginine methylation regulates Ewing sarcoma cell viability in aFrontiers in oncology · 2025Article
- Prognostic value ofHeliyon · 2023Article
- Analysis on diagnostic failure of US-guided core needle biopsy for soft tissue tumors.Research in diagnostic and interventional imaging · 2023Article
- Ewing sarcoma with very late metastasis in the skull: a case report.Journal of medical case reports · 2022Review
- Latest developments in the pathobiology of Ewing sarcoma.Journal of bone oncology · 2022Review
- A Visualized Dynamic Prediction Model for Lymphatic Metastasis in Ewing's Sarcoma for Smart Medical Services.Frontiers in public health · 2022Article
- Development of a Machine Learning-Based Predictive Model for Lung Metastasis in Patients With Ewing Sarcoma.Frontiers in medicine · 2022Article
- Article
- EWS-FLI1-targeting peptide identifies Ewing sarcoma tumor boundaries and lymph node metastasis via near-infrared imaging.Molecular oncology · 2021Article
- Review
- Identification of aberrantly methylated-differentially expressed genes and potential agents for Ewing sarcoma.Annals of translational medicine · 2021Article
- Clinical outcome of patients with recurrent or refractory localized Ewing's sarcoma family of tumors: A retrospective report from the Japan Ewing Sarcoma Study Group.Cancer reports (Hoboken, N.J.) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ewing's sarcoma (ES) is a highly aggressive and metastatic tumor in children and young adults caused by a chromosomal fusion between the Ewing sarcoma breakpoint region 1 (EWSR1) gene and the transcription factor FLI1 gene. ES is managed with standard treatments, including chemotherapy, surgery and radiation. Although the 5-year survival rate for primary ES has improved, the survival rate for ES patients with metastases or recurrence remains low. Several novel molecular targets in ES have recently been identified and investigated in preclinical and clinical settings, and targeting the function of receptor tyrosine kinases (RTKs), the fusion protein EWS-FLI1 and mTOR has shown promise. There has also been increasing interest in the immune responses of ES patients. Immunotherapies using T cells, NK cells, cancer vaccines and monoclonal antibodies have been considered for ES, especially for recurrent patients. Because understanding the pathogenesis of ES is extremely important for the development of novel treatments, this review focuses on the mechanisms and functions of targeted therapies and immunotherapies in ES. It is anticipated that integrating the knowledge obtained from basic research and translational and clinical studies will lead to the development of novel therapeutic strategies for the treatment of ES.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.